A minimally invasive procedure designed to shrink prostate tissue with a series of blasts of steam offers men a new treatment for urinary symptoms commonly associated with enlarged prostates. The procedure, called Rezūm and developed by NxThera Inc. of Maple Grove, Minn., became widely available in the U.S. in the second half of 2016.
NxThera, Inc., a medical device company pioneering the application of its convective radiofrequency thermal technology to treat endourological conditions, today announced the Humana and Aetna health care insurance plans have joined other major insurers to provide coverage of the Rezūm® System for the minimally invasive treatment of benign prostatic hyperplasia (BPH), or enlarged prostate.
SI-BONE, Inc., an innovative medical device company that pioneered the use of the iFuse Implant System® (“iFuse”), a triangular shaped minimally invasive surgical (MIS) device indicated for fusion for certain disorders of the sacroiliac (SI) joint, announced that the highly respected journal Spine has published the 50th peer-reviewed iFuse paper titled Predictors of Outcome in Conservative and Minimally Invasive Surgical Management of Pain Originating from the Sacroiliac Joint – a Pooled Analysis.
Advanced ICU Care, the nation’s leading provider of high-acuity telehealth services, announced that the company is now contracted to provide acute care and monitoring to more than 1,000 acute care patient beds across more than 65 partner hospitals in the United States.
Strata Oncology, a precision oncology company, today announced an agreement with Epizyme to support patient identification and enrollment for Epizyme’s ongoing Phase 2 clinical trial of tazemetostat in patients with relapsed or refractory non-Hodgkins lymphoma (NHL).
Cerêve Inc., manufacturer of the Cerêve Insomnia Therapy for treating people with insomnia, today announced it has appointed Donald J. Spence President and Chief Executive Officer.
Clovis Oncology, Inc. (NASDAQ: CLVS) and Strata Oncology, Inc. today announced an agreement to accelerate patient identification and enrollment for Clovis’ ongoing TRITON (Trial of Rucaparib in Prostate Indications) clinical trial program, which includes Phase 2 and Phase 3 clinical trials of rucaparib in metastatic castration-resistant prostate cancer, both of which are open for enrollment.
Arboretum Ventures, a leading healthcare venture capital firm, today announced the promotion of Tom Shehab, M.D. to Managing Director. Dr. Shehab began his career at Arboretum in 2014 as a Principal after spending several years as a member of the Arboretum Technical Advisory Board.
Digital therapy could soon be prescribed and reimbursed like a pharmaceutical drug for patients with chronic substance use disorder. “This could be a watershed moment for digital health,” said Corey McCann, MD, PhD, chief executive officer of Pear Therapeutics, the developer of the software.
Cerêve Inc., a privately-held health care company preparing to launch its FDA-cleared insomnia device, announced today the closing of a $38 million Series B round of financing led by KKR, a leading global investment firm.
No more posts to load.
Load More Posts